EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Establishing resources and increasing awareness to advance research on Dentatorubral-pallidoluysian atrophy toward a treatment: a patient organization perspective

Silvia Prades iD, Andrea Compton, Jeffrey B Carroll

Therapeutic Advances in Rare Disease · 2024-01 · 5

DOI: 10.1177/26330040241249189 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Rare Disease, online erschienen am 06.05.2024. Verfasst von Silvia Prades und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ataxia UK, 12 Broadbent Close, London N6 5JW, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dentatorubral-pallidoluysian atrophy (DRPLA) is an ultra-rare neurodegenerative disorder characterized by ataxia, cognitive decline, myoclonus, chorea, epilepsy, and psychiatric manifestations. This article delves into the multifaceted efforts of CureDRPLA, a family-driven non-profit organization, in advancing research, raising awareness, and developing therapeutic strategies for this complex condition. CureDRPLA’s inception in 2019 led to the establishment of the DRPLA Research Program, and since then have funded research projects to advance the understanding of DRPLA including but not limited to human cellular and mouse models, a natural history and biomarkers study, and a patient registry. There are currently no disease-modifying treatments for DRPLA, motivating a concerted effort on behalf of CureDRPLA to hasten their development by funding and coordinating preclinical studies of therapies in multiple modalities. Of particular interest are therapies focused on lowering the expression (or downregulation) of ATN1, the mutant gene that causes DRPLA, in hopes of tackling the pathology at its root. As with many ultra-rare diseases, a key challenge in DRPLA remains the complexity of coordinating both basic and clinical research efforts across multiple sites around the world. Finally, despite the generous financial support provided by CureDRPLA, more funding and collective efforts are still required to advance research toward the clinic and develop effective treatments for individuals with DRPLA.

Schlagwörter

Stichwörter der Autor:innen

DRPLAdrug developmentpatient advocacy grouppolyQ repeat disordersrare diseasesresearch

Autor:innen und Institutionen

  • Ataxia UK, 12 Broadbent Close, London N6 5JW, UK.
  • CureDRPLA, Brooklyn, NY, USA.
  • Department of Neurology, University of Washington, Seattle, WA, USA.

ORCID-Profile: Silvia Prades

Zitieren

APA

Prades, S., Compton, A., & Carroll, J. B. (2024). Establishing resources and increasing awareness to advance research on Dentatorubral-pallidoluysian atrophy toward a treatment: a patient organization perspective. Therapeutic Advances in Rare Disease, 5. https://doi.org/10.1177/26330040241249189

Vancouver

Prades S, Compton A, Carroll JB. Establishing resources and increasing awareness to advance research on Dentatorubral-pallidoluysian atrophy toward a treatment: a patient organization perspective. Therapeutic Advances in Rare Disease. 2024;5. doi:10.1177/26330040241249189

BibTeX
@article{Prades2024,
  author = {Prades, Silvia and Compton, Andrea and Carroll, Jeffrey B},
  title = {Establishing resources and increasing awareness to advance research on Dentatorubral-pallidoluysian atrophy toward a treatment: a patient organization perspective},
  journal = {Therapeutic Advances in Rare Disease},
  year = {2024},
  volume = {5},
  doi = {10.1177/26330040241249189}
}
Kostenlos starten →